Welcome

Recent News

2021-06-28
Securities class action litigation activity involving IPO companies recently has been a significant concern, for the companies themselves as well as for their insurers.
2018-02-04
Using data from the Stanford Securities Litigation Analytics (SSLA) database, we take a closer look at the risk facing biopharma firms with market capitalization under $1 billion, and we find that the prospects these firms face with respect to securities class actions is only slightly worse than that faced by firms of comparable size in other sectors.